• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.1975年至2005年美国肝细胞癌的发病率、死亡率及生存趋势
J Clin Oncol. 2009 Mar 20;27(9):1485-91. doi: 10.1200/JCO.2008.20.7753. Epub 2009 Feb 17.
2
Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States.美国肝细胞癌发病率和肝癌死亡率的变化。
Am J Gastroenterol. 2014 Apr;109(4):542-53. doi: 10.1038/ajg.2014.11. Epub 2014 Feb 11.
3
Hepatocellular Carcinoma Incidence Is Decreasing Among Younger Adults in the United States.美国年轻人中肝细胞癌的发病率正在下降。
Clin Gastroenterol Hepatol. 2020 Jan;18(1):242-248.e5. doi: 10.1016/j.cgh.2019.04.043. Epub 2019 Apr 28.
4
Epidemiology of hepatocellular carcinoma in Hispanics in the United States.美国西班牙裔人群肝细胞癌的流行病学
Arch Intern Med. 2007 Oct 8;167(18):1983-9. doi: 10.1001/archinte.167.18.1983.
5
Racial/ethnic disparities in hepatocellular carcinoma incidence and mortality rates in the United States, 1992-2018.美国 1992-2018 年肝细胞癌发病率和死亡率的种族/民族差异。
Hepatology. 2022 Sep;76(3):589-598. doi: 10.1002/hep.32394. Epub 2022 Apr 22.
6
Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States.美国肝细胞癌患者在癌症发病率、疾病负担及总生存率方面存在的种族/族裔特异性差异。
Cancer. 2016 Aug 15;122(16):2512-23. doi: 10.1002/cncr.30103. Epub 2016 May 19.
7
Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma.早期肝细胞癌患者在获得医疗服务和生存方面的种族/族裔差异。
Arch Surg. 2010 Dec;145(12):1158-63. doi: 10.1001/archsurg.2010.272.
8
Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012.2000年至2012年美国50个州肝细胞癌的发病率
Gastroenterology. 2017 Mar;152(4):812-820.e5. doi: 10.1053/j.gastro.2016.11.020. Epub 2016 Nov 23.
9
Socioeconomic status and hepatocellular carcinoma in the United States.美国的社会经济地位与肝细胞癌。
Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1330-5. doi: 10.1158/1055-9965.EPI-12-0124. Epub 2012 Jun 5.
10
State-Level HCC Incidence and Association With Obesity and Physical Activity in the United States.美国州级肝细胞癌发病率及其与肥胖和身体活动的关联
Hepatology. 2021 Sep;74(3):1384-1394. doi: 10.1002/hep.31811. Epub 2021 Jun 11.

引用本文的文献

1
Current knowledge about immunotherapy response after liver transplantation of patients with liver cancer.关于肝癌患者肝移植后免疫治疗反应的当前知识。
J Liver Transpl. 2025 Aug;19. doi: 10.1016/j.liver.2025.100285. Epub 2025 Jun 6.
2
Combining serologic biomarkers with the PAGE B score improves risk stratification for hepatocellular carcinoma development among chronic hepatitis B patients.将血清学生物标志物与PAGE B评分相结合可改善慢性乙型肝炎患者发生肝细胞癌的风险分层。
Sci Rep. 2025 Aug 26;15(1):31471. doi: 10.1038/s41598-025-16059-5.
3
Radiomics-based machine-learning method to predict extrahepatic metastasis in hepatocellular carcinoma after hepatectomy: a multicenter study.基于影像组学的机器学习方法预测肝癌肝切除术后肝外转移:一项多中心研究
Sci Rep. 2025 Aug 14;15(1):29784. doi: 10.1038/s41598-025-15406-w.
4
Hepatocellular carcinoma in patients without cirrhosis.无肝硬化患者的肝细胞癌
World J Gastroenterol. 2025 Jun 21;31(23):107100. doi: 10.3748/wjg.v31.i23.107100.
5
Tenofovir disoproxil fumarate versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma after surgical resection: a systematic review and meta-analysis.替诺福韦酯与恩替卡韦对乙型肝炎病毒相关肝细胞癌手术切除后预后的影响:一项系统评价和荟萃分析
Front Oncol. 2025 May 27;15:1462794. doi: 10.3389/fonc.2025.1462794. eCollection 2025.
6
An Examination of Liver Cancer Incidence in California.加利福尼亚州肝癌发病率调查
J Registry Manag. 2024 Winter;51(4):136-145.
7
Usefulness of multiphasic MRI in assessing suitability for SIRT in treatment of liver malignancies.多期磁共振成像在评估肝脏恶性肿瘤患者接受选择性内放射治疗(SIRT)的适用性中的作用
Abdom Radiol (NY). 2025 Mar 17. doi: 10.1007/s00261-025-04875-2.
8
The epigenetic basis of hepatocellular carcinoma - mechanisms and potential directions for biomarkers and therapeutics.肝细胞癌的表观遗传基础——生物标志物与治疗方法的机制及潜在方向
Br J Cancer. 2025 Jun;132(10):869-887. doi: 10.1038/s41416-025-02969-8. Epub 2025 Mar 8.
9
Application of Indirect ELISA and PCR Techniques for Detecting of Hepatocellular Carcinoma using Des-gamma Carboxyprothrombin, Alpha-fetoprotein, and Thioredoxin Biomarkers.使用去γ羧基凝血酶原、甲胎蛋白和硫氧还蛋白生物标志物的间接酶联免疫吸附测定法和聚合酶链反应技术在肝细胞癌检测中的应用
Mol Biotechnol. 2025 Feb 25. doi: 10.1007/s12033-025-01401-z.
10
Prevalence and prediction of hepatocellular carcinoma in alcohol-associated liver disease: a retrospective study of 136 571 patients with chronic liver diseases.酒精性肝病中肝细胞癌的患病率及预测:一项对136571例慢性肝病患者的回顾性研究
eGastroenterology. 2024 Jan 19;2(1):e100036. doi: 10.1136/egastro-2023-100036. eCollection 2024 Jan.

本文引用的文献

1
Molecular targeted therapies in hepatocellular carcinoma.肝细胞癌的分子靶向治疗
Hepatology. 2008 Oct;48(4):1312-27. doi: 10.1002/hep.22506.
2
National trends and disparities in the incidence of hepatocellular carcinoma, 1998-2003.1998 - 2003年肝细胞癌发病率的全国趋势及差异
Prev Chronic Dis. 2008 Jul;5(3):A74. Epub 2008 Jun 15.
3
Hepatitis B virus (HBV) infection in Asian and Pacific Islander Americans (APIAs): how can we do better for this special population?亚裔和太平洋岛民美国人(APIAs)中的乙型肝炎病毒(HBV)感染:我们如何能为这一特殊人群做得更好?
Am J Gastroenterol. 2008 Jul;103(7):1824-33. doi: 10.1111/j.1572-0241.2008.01878.x. Epub 2008 May 13.
4
Diagnosis and treatment of hepatocellular carcinoma.肝细胞癌的诊断与治疗
Gastroenterology. 2008 May;134(6):1752-63. doi: 10.1053/j.gastro.2008.02.090.
5
Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US population.美国人群肝细胞癌局部治疗趋势及生存结果
Am J Surg. 2008 Jun;195(6):829-36. doi: 10.1016/j.amjsurg.2007.10.010. Epub 2008 Apr 23.
6
Surveillance for acute viral hepatitis--United States, 2006.2006年美国急性病毒性肝炎监测
MMWR Surveill Summ. 2008 Mar 21;57(2):1-24.
7
High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma.高病毒载量和乙型肝炎病毒C基因型e亚型与肝细胞癌风险增加相关。
J Clin Oncol. 2008 Jan 10;26(2):177-82. doi: 10.1200/JCO.2007.13.2043.
8
Hepatitis B awareness, knowledge, and screening among Asian Americans.亚裔美国人对乙肝的认知、了解及筛查情况
J Cancer Educ. 2007 Winter;22(4):266-72. doi: 10.1007/BF03174128.
9
Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives.《1975 - 2004年美国癌症现状年度报告:聚焦美国印第安人和阿拉斯加原住民的癌症情况》
Cancer. 2007 Nov 15;110(10):2119-52. doi: 10.1002/cncr.23044.
10
Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry.终末期肝病中肝铁过载的患病率及其与肝细胞癌的关联:来自国家血色素沉着症移植登记处的结果
Liver Int. 2007 Dec;27(10):1394-401. doi: 10.1111/j.1478-3231.2007.01596.x. Epub 2007 Oct 9.

1975年至2005年美国肝细胞癌的发病率、死亡率及生存趋势

Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

作者信息

Altekruse Sean F, McGlynn Katherine A, Reichman Marsha E

机构信息

Division of Cancer Control and Population Sciences, and the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20892-8316, USA.

出版信息

J Clin Oncol. 2009 Mar 20;27(9):1485-91. doi: 10.1200/JCO.2008.20.7753. Epub 2009 Feb 17.

DOI:10.1200/JCO.2008.20.7753
PMID:19224838
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2668555/
Abstract

PURPOSE

Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide. Incidence rates are increasing in the United States. Monitoring incidence, survival, and mortality rates within at-risk populations can facilitate control efforts.

METHODS

Age-adjusted incidence trends for HCC were examined in the Surveillance, Epidemiology, and End Results (SEER) registries from 1975 to 2005. Age-specific rates were examined for birth cohorts born between 1900 and 1959. Age-adjusted incidence and cause-specific survival rates from 1992 to 2005 were examined in the SEER 13 registries by race/ethnicity, stage, and treatment. United States liver cancer mortality rates were also examined.

RESULTS

Age-adjusted HCC incidence rates tripled between 1975 and 2005. Incidence rates increased in each 10-year birth cohort from 1900 through the 1950s. Asians/Pacific Islanders had higher incidence and mortality rates than other racial/ethnic groups, but experienced a significant decrease in mortality rates over time. From 2000 to 2005, marked increases in incidence rates occurred among Hispanic, black, and white middle-aged men. Between 1992 and 2004, 2- to 4-year HCC survival rates doubled, as more patients were diagnosed with localized and regional HCC and prognosis improved, particularly for patients with reported treatment. Recent 1-year survival rates remained, however, less than 50%.

CONCLUSION

HCC incidence and mortality rates continue to increase, particularly among middle-aged black, Hispanic, and white men. Screening of at-risk groups and treatment of localized-stage tumors may contribute to increasing HCC survival rates in the United States. More progress is needed.

摘要

目的

肝细胞癌(HCC)是全球癌症死亡的第三大主要原因。在美国,其发病率正在上升。监测高危人群的发病率、生存率和死亡率有助于防控工作。

方法

在监测、流行病学和最终结果(SEER)登记处中研究了1975年至2005年HCC的年龄调整发病率趋势。对1900年至1959年出生队列的年龄别发病率进行了研究。在SEER 13登记处中按种族/民族、分期和治疗情况研究了1992年至2005年的年龄调整发病率和病因特异性生存率。还研究了美国肝癌死亡率。

结果

1975年至2005年期间,年龄调整后的HCC发病率增长了两倍。从1900年到20世纪50年代,每一个10年出生队列的发病率都有所上升。亚裔/太平洋岛民的发病率和死亡率高于其他种族/民族群体,但随着时间的推移死亡率显著下降。2000年至2005年期间,西班牙裔、黑人和白人中年男性的发病率显著上升。1992年至2004年期间,HCC的2至4年生存率翻了一番,因为更多患者被诊断为局限性和区域性HCC且预后改善,尤其是接受了报告治疗的患者。然而,最近的1年生存率仍低于50%。

结论

HCC的发病率和死亡率持续上升,尤其是在中年黑人、西班牙裔和白人男性中。对高危人群进行筛查以及对局限性期肿瘤进行治疗可能有助于提高美国HCC的生存率。仍需取得更多进展。